Q2 Earnings Estimate for DBVT Issued By HC Wainwright

DBV Technologies S.A. (NASDAQ:DBVT - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for DBV Technologies in a note issued to investors on Monday, May 5th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of ($0.28) for the quarter. HC Wainwright currently has a "Buy" rating and a $16.00 target price on the stock. The consensus estimate for DBV Technologies' current full-year earnings is ($7.05) per share. HC Wainwright also issued estimates for DBV Technologies' Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.31) EPS and FY2029 earnings at $0.37 EPS.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. The firm had revenue of $0.51 million for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%.

Other equities research analysts also recently issued research reports about the company. StockNews.com raised DBV Technologies from a "sell" rating to a "hold" rating in a report on Friday. JMP Securities lifted their target price on shares of DBV Technologies from $10.00 to $15.00 and gave the stock a "market outperform" rating in a report on Thursday, May 1st.

DBV Technologies Stock Down 0.1 %

Shares of NASDAQ DBVT traded down $0.01 during trading hours on Tuesday, hitting $9.83. The company had a trading volume of 64,403 shares, compared to its average volume of 186,393. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $10.12. The firm's 50 day moving average is $6.91 and its 200-day moving average is $4.88. The stock has a market capitalization of $269.24 million, a P/E ratio of -2.18 and a beta of -0.66.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent reporting period. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.